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BACKGROUND. Autoimmune inner ear disease (AIED) is a rare disease that results in progressive sensorineural hearing
loss. Patients with AIED initially respond to corticosteroids; however, many patients become unresponsive to this
treatment over time, and there is no effective alternative therapy for these individuals.
METHODS. We performed a phase I/II open-label, single-arm clinical trial of the IL-1 receptor antagonist anakinra in
corticosteroid-resistant AIED patients. Given that the etiology of corticosteroid resistance is likely heterogeneous, we
used a Simon 2-stage design to distinguish between an unacceptable (≤10%) and an acceptable (≥30%) response rate
to anakinra therapy. Subjects received 100 mg anakinra by subcutaneous injection for 84 days, followed by a 180-day
observational period.
RESULTS. Based on patient responses, the Simon 2-stage rule permitted premature termination of the trial after 10
subjects completed the 84-day drug period, as the target efficacy for the entire trial had been achieved. Of these 10
patients, 7 demonstrated audiometric improvement, as assessed by pure tone average (PTA) and word recognition score
(WRS). In these 7 responders, reduced IL-1β plasma levels correlated with clinical response. Upon discontinuation of
treatment, 3 subjects relapsed, which correlated with increased IL-1β plasma levels.
CONCLUSION. We demonstrated that IL-1β inhibition in corticosteroid-resistant AIED patients was effective in a small
cohort of patients and that IL-1β plasma levels associated with both clinical hearing response and disease relapse. These
results suggest that a larger phase II randomized clinical trial of IL-1β inhibition is warranted.
TRIAL REGISTRATION. ClinicalTrials.gov NCT01267994.
FUNDING. NIH, Merrill & Phoebe Goodman Otology Research Center, and Long Island Hearing & Speech Society.

Introduction

Potentially reversible, immune-mediated, sensorineural hearing
loss (SNHL) can be divided into 2 subgroups: autoimmune inner
ear disease (AIED) and sudden SNHL (SSNHL). Patients with AIED
usually experience multiple episodes of rapid hearing loss, either
concurrently or sequentially, in both ears, whereas SSNHL is usually
a unilateral, isolated event. The mechanisms that control corticosteroid-responsive immune-mediated SNHL remain enigmatic, in
large part, because AIED is a rare disease, worthy of orphan disease
classification, and SSNHL is likely heterogeneous in etiology. For
patients that experience an acute, sensorineural decline in hearing,
timely corticosteroid administration may result in preservation of
some or all hearing in approximately 60% of patients with either

Related Attending physician: p. 3685
Conflict of interest: Andrea Vambutas and the Feinstein Institute for Medical Research
have filed a patent for the use of IL-1 antagonists in the treatment of AIED, SSNHL, and
Meniere’s disease.
Submitted: April 7, 2014; Accepted: June 12, 2014.
Reference information: J Clin Invest. 2014;124(9):4115–4122. doi:10.1172/JCI76503.

AIED (1) or SSNHL (2). Unfortunately, alternate medical therapies
for the 40% that fail to respond to corticosteroids have proven largely ineffectual. Therefore, the majority of interventions following corticosteroid failure are rehabilitative, involving either hearing aids or
cochlear implants. Interestingly, the influence of plasma cytokines
has not been investigated to any great degree in this disorder, largely
because the events in the cochlea may not be reflected in the peripheral blood immune cells (PBMCs). Furthermore, since AIED is a rare
disease, studies of these patients are often difficult to implement.
We initially examined patients with end-stage AIED, who were
candidates for cochlear implants, and compared them with cochlear implant candidates with nonimmunologic etiologies of hearing loss. We harvested cochlear perilymph at the time of cochlear
implant surgery and used it to stimulate autologous PBMCs. We
identified that the 2 groups differed with respect to expression of
the IL-1 type II decoy receptor (IL-1R2) in PBMCs in response to
autologous perilymph (3). The decoy receptor sequesters IL-1, yet
has no downstream signaling, thereby preventing inflammation
(4). These initial observations led to further investigation of the
cytokines in the peripheral blood of steroid-sensitive and steroidresistant AIED patients. Consistent with the increased expression
jci.org   Volume 124   Number 9   September 2014
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Figure 1. CONSORT flow diagram. For enrollment, all patients must have been treated with a 28-day course of prednisone and have experienced no clinical
improvement, as assessed by PTA and WRS. All patients that met enrollment criteria were allocated to receive the intervention (n = 13). Of the 13 subjects,
1 never received anakinra. Of the 12 patients that received anakinra, 2 were unable to complete the initial 28 days of therapy, leaving 10 subjects evaluable
for the efficacy assessment.

of the IL-1R2 decoy receptor in steroid-resistant AIED patients
(3), we observed increased expression of IL-1β in these steroidresistant individuals (5). Moreover, whereas dexamethasone was
unable to prevent IL-1β release in the PBMCs of these patients,
anakinra effectively prevented IL-1β release (5). Anakinra is an IL-1
receptor antagonist that competitively inhibits IL-1 binding to the
cognate IL-1 type I receptor, thereby blocking the biologic activity
of IL-1β and IL-1α (6). This observation became the rationale for
the present clinical trial in steroid-resistant AIED patients.
SNHL related to IL-1β expression has also been observed in
a rare disease, Muckle-Wells disease (MWS), in which a gain-offunction mutation in NLRP3 results in excessive IL-1β release (7, 8).
In this autosomal-dominant disease, patients experience skin
rashes, periodic fevers, and SNHL. Unlike MWS patients, AIED
patients do not have an afflicted first-degree relative, skin rash,
or fever. Moreover, although the majority of AIED patients are
initially steroid responsive (70%), that response is lost over time
in all but 14% of patients (9). Furthermore, whereas IL-1β inhibition is quite effective at controlling the systemic manifestations
of MWS, only 3 of 14 patients experienced minor improvement
in auditory acuity with IL-1 inhibition (10), despite isolated case
reports of significant greater hearing recovery (11, 12).

Results

Characteristics of the study population. During a 3-year period
(December 2010 to January 2014), 14 patients were screened, 13
4116
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of which enrolled into this single-center, phase I/II open-label
study (Figure 1). Of these 13 patients, 12 received anakinra, as
patient LIJ-10 passed the screening process, but was not started on
drug because of development of a systemic infection in the interim. Demographics of age, gender, concurrent autoimmune conditions, other diseases, and medications are outlined in Table 1.
Of the 12 patients, 10 were evaluable for efficacy (Figure 1), as 2
patients were unable to complete the requisite initial 28 days of
therapy required to assess efficacy. Results reported follow the
2010 CONSORT guidelines as applicable (13). Notably, both the
patient reporting uveitis (LIJ-03) and the single teenaged patient
(LIJ-09) were identified to be sequence-negative for NLRP3 mutations, excluding a diagnosis of MWS.
Efficacy. As per protocol, 10 patients were enrolled in the first
stage, and 8 of these completed the 84-day therapy period at the
time of interim analysis. Of these 8, 5 were classified as responders
by PTA score, which triggered enrollment into the second stage.
At the time enrollment began in the second stage, patients LIJ-09
and LIJ-10 had not yet completed the 84-day observation period
(but ultimately yielded 1 responder and 1 that never instituted
treatment). During this time, 3 stage II patients were enrolled, for
a trial total of 13.
Of the total 13 subjects, 2 withdrew from treatment within the
first 28 days, and 1 never initiated treatment, leaving 10 subjects
evaluable for efficacy assessment. Per protocol, responsive patients
were defined as having ≥5 decibel (dB) improvement in PTA in the
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Table 1. Demographics of enrolled subjects
Patient

Demographics

Autoimmune disease/
significant medical history

Concomitant medications
at enrollment

Anakinra study
treatment

Additional anakinra
treatment given after
84-day course

LIJ-01
LIJ-02

37-year-old female
49-year-old female

Yes
No

33-year-old female
46-year-old female

Hypertension, elevated cholesterol

Treatment aborted prior to
28-day course
Completed 84 days

N/A

LIJ-04
LIJ-05
LIJ-06

61-year-old male
54-year-old male

Psoriasis
Prior myocardial infarction/stent
insertion, hypertension

Completed 84 daysA
Completed 84 days

NoA
Yes

LIJ-07
LIJ-08
LIJ-09
LIJ-10
LIJ-11

53-year-old male
46-year-old male
15-year-old female
64-year-old male
59-year-old male

Completed 84 days
Completed 84 days
Completed 84 days
No study treatment initiated
Completed 84 days

No
No
Yes
N/A
Yes

LIJ-12
LIJ-14

41-year-old male
57-year-old female

Asthma
None
None
Hyperthyroidism
Ulcerative colitis, melanoma
(20 years prior), septal squamous cell
carcinoma (9 years prior)
None
None

Calcium-D, multivitamin
Synthroid, Dyazide,
vitamin D, multivitamin
Dyazide, multivitamins,
birth control pill, Allegra
Singulair, simvastin, Zyrtec, Ambien, K-LOR,
Dyazide, Zoloft, Flonase, allergy shots
Potassium
Metaprolol, Vytorin, lisinopril,
Nexium, aspirin, Lovanza, vitamin D,
Niaspan, calcium, Uroxatrol
Zocor, Combivent, Elavil, Valium
Dyazide, aspirin, vitamins
None
None
Diamox, Asacol, Librax, Xanax

Completed 84 days
Completed 84 days

LIJ-03

None
Grave’s disease (age 30 years; treated
with radioactive iodine)
Meningitis, asthma, kidney stones

Completed 84 days
Treatment aborted prior to
completion of first 28-day course

No
N/A

None
Multivitamin

No

Patient refused to stop study medication.

A

active ear, or as having ≥12% improvement in WRS, in response to
anakinra at any point during the 28th to 84th day. Among the 10
evaluable subjects (those who completed 84 days of therapy), 7 of 10
(patients LIJ-01, LIJ-02, LIJ-04, LIJ-05, LIJ-07, LIJ-09, and LIJ-11;
70%) met the criteria for response by PTA, and 7 of 10 (patients
LIJ-01, LIJ-02, LIJ-04, LIJ-06, LIJ-07, LIJ-09, and LIJ-11; 70%) met
the criteria of response by WRS. The results comparing anakinra
responders and nonresponders were statistically significant for
PTA and WRS (both P = 0.02, Mann-Whitney test; Figure 2). In
a prior clinical trial that evaluated the efficacy of methotrexate in
steroid-sensitive AIED, therapeutic efficacy as measured by pure
tones was defined as either a 15 dB improvement at 1 frequency or
a 10 dB improvement at 2 contiguous frequencies (14). This efficacy assessment was difficult to use in the present study because
of its long duration (264 days) and multiple points of assessment,
and would not account for possible simultaneous or sequential
improvements and declines at different frequencies. Nonetheless,
we did assess whether the enrolled subjects met the criteria for
PTA improvement based on the existing criteria. Specifically, we
queried whether the criteria for improvement were met during the
treatment period, relative to the initial audiogram prior to starting
anakinra. Notably, when using the criteria set forth in the methotrexate trial, the results yielded 1 additional responder: patient
LIJ-06 now met the definition for responder by PTA as well. As a
result, in a per-protocol assessment, an 80% response rate would
be achieved using these alternate criteria for clinical improvement in PTA. WRS criteria for improvement were the same for
this trial and prior trials. Interestingly, for patient LIJ-05, WRS

improvement was limited, and may have been artificially low due
to a ceiling effect: the patient’s starting WRS score was 88%, which
improved to 90% at the end of 28 days and to 100% by the 84th
day. By the best interval response (see Figure 3), this patient would
be classified as a nonresponder. Because by both endpoints, PTA
and WRS, the criterion of ≥6 responders of a maximum 29 to reject
the null hypothesis was achieved, the trial was prematurely terminated at the recommendation of the Data and Safety Monitoring
Board (DSMB), since evidence for efficacy had been supported.
Of the patients treated with anakinra in this clinical trial, there did
not appear to be a correlation between audiometric configuration
and the ability to respond: patients derived benefit with up-sloping,
down-sloping, flat, and U-shaped audiograms (data not shown).
Although this was not a randomized clinical trial, the results
could also be interpreted by an intention-to-treat (ITT) analysis.
There were a total of 13 subjects enrolled, 1 of whom could not start
the trial, due to logistical reasons unrelated to the trial itself. We
would not include this subject in the ITT analysis. Of the remaining 12 patients, 2 dropped out due to toxicity (intolerable injection
site reactions) and would be counted in the ITT analysis, yielding
a response rate of 7 of 12 (58%). Even this more conservative ITT
rate of 58% is substantially higher than our initial hypothesis of a
30% response rate being clinically meaningful.
Adverse events and subject withdrawals. Injection site reactions
were the most common adverse event, observed in approximately
70% of patients. This observed rate was consistent with use of
anakinra in other diseases (15). Of the 13 eligible patients, 2 were
withdrawn from further study during the anakinra treatment phase:
jci.org   Volume 124   Number 9   September 2014
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Figure 2. Best hearing improvement observed while on anakinra therapy.
PTA improvement (A) and WRS improvement (B) during the 84-day drug
period were both significantly higher in anakinra responders (n = 7) versus
nonresponders (n = 3) (P = 0.02 for both, Mann-Whitney test). The result
was also compared with the historic improvement with corticosteroid
therapy (Standard of care) previously reported by Niparko et al. (1).

LIJ-06, and LIJ-09). The relapse was associated with increasing
IL-1β, although a common absolute threshold value was not identified for relapse. Notably, although patient LIJ-08 was considered an
anakinra failure, upon discontinuing drug, her IL-1β levels declined
and her hearing clinically improved (Figure 3). These findings suggest that although anakinra was not effective in modulating IL-1β
levels in this patient, reduction in her circulating IL-1β appeared to
be linked to audiometric improvement. Plasma levels of IL-1α were
also measured at all time points in each subject. No IL-1α could be
detected in the samples assayed (data not shown).

Discussion

patients LIJ-03 and LIJ-14 did not complete the initial 28 days
of treatment because of intolerable injection site reactions. During the observational period, 3 patients were withdrawn. Patient
LIJ-05, one of the responders, was terminated from further trial
participation at day 84, as the patient refused to discontinue drug.
Patient LIJ-12 withdrew at visit 5 because of failure of drug efficacy.
In patient LIJ-07, use of anakinra appeared to modulate the ability
to respond to steroids: the patient initially responded to anakinra,
but subsequently worsened by day 84. He was placed on prednisone at day 84, and rapidly became corticosteroid responsive at
that point, whereas he previously failed to respond to prednisone.
He withdrew from the study following the steroid therapy.
Laboratory studies demonstrated few abnormalities and
no evidence of neutropenia. No elevations of creatinine were
observed. Several patients were identified to have mild, asymptomatic hypokalemia during the course of the trial. These patients
were treated with potassium replacement; however, the etiology of
the hypokalemia was not felt to be a result of the anakinra therapy.
IL-1β plasma levels. We sought to determine the association
between clinical responsiveness and biomarkers. Based on the
rationale for this trial that elevated IL-1β may be associated with
corticosteroid resistance, we focused our analysis on IL-1β. Plasma
levels of IL-1β were measured at all interval visits. Notably, IL-1β
plasma levels were generally associated with clinical response and,
perhaps more importantly, with clinical relapse (Figure 3). During
the 180 day post-treatment observation phase, 3 patients who experienced initial improvement in hearing while taking anakinra exhibited relapse 30–90 days after its discontinuation (patients LIJ-01,
4118
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Here, anakinra demonstrated clinical efficacy in this small sample
of corticosteroid-resistant AIED patients. Prior to these studies,
no effective therapies have been identified for corticosteroidresistant AIED patients. Moreover, no alternative effective therapies have been identified in corticosteroid-sensitive patients (14,
16, 17). Finally, even gains in steroid-sensitive AIED patients using
corticosteroid therapy may be limited. In the serial audiometry
trial for AIED, the average hearing improvement in AIED patients
after 1 month of corticosteroid therapy was 4.1 dB for PTA and 7%
for WRS (1). During the anakinra trial, the average PTA improvement was 12 dB in anakinra responders compared with 3 dB in
nonresponders (Figure 2A). Similarly, the WRS improvement was
28% in anakinra responders and 6% in nonresponders (Figure 2B).
Especially in instances of more significant hearing loss, WRS
improvements were more clinically significant, as WRS scores
reflect speech comprehension and therefore can distinguish
the ability (or lack thereof) to derive benefit from hearing aids.
Although the anakinra study had substantially fewer enrollees,
the response rate is certainly encouraging compared with the gold
standard of corticosteroid responses.
In patients with MWS, only minor improvements in auditory
acuity have been observed (10), which suggests that corticosteroid-resistant AIED is a distinct disease process. This distinction
is further supported by the fact that unlike MWS, in which inheritance is autosomal-dominant, in AIED we are yet to identify an
afflicted first-degree relative. Furthermore, whereas in MWS, the
audiometric pattern observed is usually a high-frequency SNHL,
in the AIED patient cohort, the audiometric pattern was highly
variable (data not shown) and did not correlate with the ability to
respond to anakinra.
One of the most difficult aspects in conducting studies on AIED
patients is the fluctuating nature of the hearing loss, and the potential for interpretation of efficacy of an intervention rather than
improvement as a natural fluctuation of disease. In these studies,
reduction of plasma IL-1β correlated with clinical hearing improvement within the first 28 days of anakinra therapy in patients LIJ-02,
LIJ-04, LIJ-07, LIJ-09, and LIJ-11. Although hearing fluctuation
was observed during both the 84-day drug intervention period

The Journal of Clinical Investigation  
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Figure 3. Hearing thresholds (PTA and WRS) relative to IL-1β plasma levels in a phase I/II trial of anakinra for corticosteroid-resistant AIED
(NCT01267994). At visit 1, anakinra (daily subcutaneous injectable medication) was instituted (↑) for the next 84 days, after which therapy was discontinued
(↓). Interval audiograms were obtained at visits 2 (day 28), 3 (day 56), and 4 (day 84). The 180-day post-treatment observational period is shown in visits
5 (day 114), 6 (day 174), and 7 (day 264). The left axis shows PTA, plotted inversely, similar to an audiogram (lower numbers correspond to better hearing);
solid lines denote active ears (blue, left; red, right), and dashed lines denote inactive ears. Numeric values show WRS for the active ear (blue, left; red, right),
with a best possible score of 100. The right axis shows IL-1β plasma values (green). In some patients, after visit 4, anakinra treatment was reinstated for an
additional 28 days (denoted by arrows) because of a decline in hearing. Institution of steroid therapy in patient LIJ-07 is denoted by a red arrow.

and the subsequent 180-day observational period, this fluctuation
in response to unknown stimuli is one of the clinical features of
AIED. Notably, no clinical hearing improvement or fluctuation was
observed in response to the initial corticosteroid therapy, as was
requisite for entrance into the trial. Even more intriguing, clinical
relapse within 30–90 days in several patients once anakinra was

discontinued correlated with elevation of their IL-1β levels. Reintroduction of anakinra in patients LIJ-01 and LIJ-09 resulted in
clinical hearing improvement again, albeit not to the degree seen
with initial treatment. This observation supports our hypothesis
that IL-1β is a critical mediator of immune-mediated SNHL, yet
also underscores the potential need for long-term inhibition and/or
jci.org   Volume 124   Number 9   September 2014
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Table 2. Adverse event listings (all causalities)
Adverse eventA
Injection site reaction
Injection site reaction
Headache
Vertigo
Influenza-like illness
Sinusitis
Dermatitis
Nausea
Visual impairment (floaters)
Arthralgia
Wheezing
Disturbance in attendance
Tremor (hand)
Anxiety
Cellulitis
Psoriasis (flare-up)
Tinnitus

No. subjects
reporting

Incidence
rate

Severity

Related to
study treatment

Study day or range
of event reported

Action taken

8
2
4
3
1
1
1
2
1
1
1
1
1
1
1
1
2

66.7%
16.7%
33.33%
25%
8.3%
8.3%
8.3%
16.7%
8.3%
8.3%
8.3%
8.3%
8.3%
8.3%
8.3%
8.3%
16.7%

Mild
Moderate
Mild
Mild
Mild
Mild
Mild
Mild
Mild
Mild
Moderate
Mild
Mild
Mild
Mild
Mild
Mild

Definite
Definite
Possible
Possible
Possible
Possible
Unlikely
Possible
Possible
Unlikely
Possible
Possible
Unlikely
Unlikely
Possible
Possible
Possible

10 ± 4 to 42 ± 20B
11 ± 1.4 to 23 ± 0.7B
3–8, 1–3, 20–34, 81–102
9–11, 16–17, 20–34
43–47
65–84
148–151
1–2, 16–17
65
29–30
12
20–34
5–66
63
40–46
31–42
222–236, 37–235

Ice/site rotation
Regimen interrupted/study discontinued
None or additional OTC therapy
None or additional therapy
None
Additional therapy (oral antibiotic)
Additional therapy (cortisone cream)
None
None
None
Regimen interrupted/study discontinued
None
None
None
Additional therapy (oral antibiotic)
None
None

n = 12 subjects treated with anakinra. APreferred AE MedDRA term (version 2011.02). BRange ± SD.

longer-acting agents. To date, none of the interventional clinical
trials on AIED patients have successfully correlated a plasma biomarker with pharmaceutical efficacy. Correlation of IL-1β levels
with disease severity and efficacy of anakinra is therefore novel,
and an important avenue of further exploration and validation.
IL-1 inhibition in AIED may represent yet another example of
the spectrum of diseases in which IL-1 plays a pivotal role (18). Validation of IL-1β inhibition through larger phase II and phase III trials in AIED will determine efficacy in terms of hearing restoration
as well as the potential of plasma IL-1β as a predictive biomarker of
hearing fluctuation. Future clinical trials will also identify whether
similar efficacy can be achieved in a more ethnically and racially
diverse patient population. These data provide strong evidence
that a placebo-controlled phase II trial of IL-1β inhibition in the
corticosteroid-resistant AIED patients is warranted.

Methods

Patients. To be eligible for this clinical trial, the patient (age between
13 and 75) must have bilateral SNHL, with active deterioration in 1
ear, and must have failed to respond to high-dose corticosteroids
(defined as taking 60 mg prednisone for 14 days followed by a taper,
totaling 28 days of prednisone therapy). Specifically, patients must
have SNHL of >30 dB at 1 or more frequencies in 1 or 2 ears with evidence of active deterioration (elevated threshold) in at least 1 ear of
15 dB at 1 frequency (excluding 250 or 8 kHz as a sole indicator) on
their audiogram, or 10 dB at ≥2 frequencies developing in no less than
3 and no more than 90 days; if the hearing loss evolved in less than
3 days, the patient displayed features suggestive of an autoimmune
disorder. Furthermore, hearing declines could not be accompanied
by concurrent disabling vertigo, as this clinical presentation would be
more consistent with Meniere’s disease.
The definition of steroid failure was exhibiting <5 dB PTA
improvement (PTA defined as the average of 250, 500, 1,000, 2,000,
4120
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and 4,000 Hz) and ≤12% WRS improvement. Since WRS was used as
an endpoint, all enrolled patients were required to use English as their
native language, as this test could not be administered in other languages by our study personnel. Concurrent intratympanic steroid therapy may have been used, but could not substitute for oral therapy. All
patients were of mixed European descent; age and gender are listed in
Table 1. Patients may have concurrent autoimmune diseases (Table 1).
Because AIED is a rare disease, recruitment of an untreated control
group was not feasible. Moreover, a placebo arm was equally problematic from ethical and practical standpoints, as anakinra requires daily
subcutaneous injections. The likelihood of a placebo effect was highly
improbable, as trial enrollment required 2 sequential audiograms,
prior to and following steroids, which demonstrated no improvement
with standard corticosteroid therapy.
Patients were excluded from study participation for radiologic
abnormalities suggestive of alternate SNHL etiologies, evidence of
chronic infection that would increase the risk of anakinra therapy, or
laboratory abnormalities that would also increase the risk of anakinra
therapy. MRI was used to exclude patients with retrocochlear pathology (vestibular schwannoma) or inner ear malformations. Patients
with a history of chronic infections, or treatment of a malignancy
within 3 years prior to enrollment, were similarly excluded. Additionally, patients receiving recent methotrexate or TNF antagonist
therapy were also prevented from participating. Patients that demonstrated evidence of neutropenia or renal insufficiency or failure
were also excluded. Finally, patients with latex allergy and allergy to
E. coli–derived products were excluded because of the manner in
which anakinra is formulated and packaged.
Experimental therapy. All eligible patients were treated with 84
continuous days of 100 mg subcutaneous anakinra daily injections
followed by a 180-day observational period to determine the stability
of hearing following use of anakinra (Figure 1). Retreatment during
the observational period was provided to patients that initially dem-
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onstrated clinical improvement on anakinra, but exhibited relapse in
the absence of drug. This consisted of 28 continuous days of 100 mg
subcutaneous anakinra injections, followed by continued observation.
Measures of clinical improvement. Patients were reassessed a minimum of 7 times during this clinical trial. Following the initial audiogram at the point of steroid failure, patients were reassessed every
28 days while on anakinra (days 28, 56, and 84). They were reassessed
on days 30, 90, and 180 of the observational period (days 114, 174, and
264, respectively, relative to therapy initiation). Additionally, if they
reported a hearing decline at any point during the entire trial, they
were asked to return for audiometric testing. If retreated with anakinra
for a confirmed decline in hearing, an audiogram at the 28th day of
anakinra therapy was obtained.
Hearing was measured by several audiologists, all masked to prior
audiograms. PTA was measured on a GSI-61 audiometer, calibrated
every 3 months. WRS was performed by recorded speech, 50 word
lists, rotating the track number at each visit, maintaining the same
level of difficulty.
A positive clinical response was classified as an improvement in
PTA hearing of ≥5 dB at the 5-frequency average described above, or
a ≥12% improvement in WRS, at any point between the 28th and 84th
day of trial participation. Although the criteria of a 15 dB improvement
at 1 frequency or a 10 dB improvement at 2 frequencies has been previously used to measure responsiveness in other studies (14), this model
does not account for evaluation at multiple time points, and thus could
not be used in the present study.
The DSMB recommended closing the trial when >6 of a total 29
evaluable patients achieved the efficacy target of PTA improvement
between the 28th and 84th day of treatment with anakinra, as dictated
by the Simon 2-stage design.
Safety laboratory measures. To screen for eligibility and to assess
safety during the trial, a CBC with differential, and SMA-7 was
obtained from all participants at each visit. A β-HCG was obtained in
all female participants at each visit. Notably, 1 patient initially failed
the screen for trial inclusion because of a positive β-HCG. This patient
was enrolled >12 months later once she met eligibility criteria again.
No patients failed screening or were prevented from using anakinra
during the trial for concerns of neutropenia.
Experimental laboratory measures. At the time of initial enrollment and at all visits, safety blood and blood biomarker identification was obtained, with the hope that anakinra responders and
nonresponders could be identified based on their peripheral blood
expression of various cytokines, most importantly IL-1β and IL-1α.
Plasma was collected and stored at –20°C until a complete set of
samples was acquired for each enrolled subject. Frozen samples
were thawed immediately prior to analysis, and none of the samples
underwent repetitive freeze-thawing cycles prior to analysis. IL-1β
and IL-1α levels in plasma were quantified using a sandwich ELISA
(R&D Systems) as previously described (5). All samples were run in
duplicate; mean variance was ≤0.02%.
Statistics and sample size calculation. Because steroid-resistant
subjects were to be enrolled, and because we assumed that multiple
etiologies may contribute to the failure to respond to steroids, we
proposed that a ≤10% response rate would be unacceptable, and a
≥30% response rate would be clinically meaningful and worthy of
further study. A Simon 2-stage “optimal” design was used: 10 subjects would be treated in the first stage; if 2 or more responded, the

trial would enroll 19 additional subjects; if ≥6 of all 29 responded,
then anakinra would be considered effective and a candidate for
further larger trials. This design corresponded to testing the null
hypothesis that the true objective response rate was ≤10% versus the
alternative hypothesis that the true response rate was ≥30%, with
α = 0.05 and power = 0.80.
Given that 2 sequential audiograms (before and after steroid therapy) were required for trial eligibility, the likelihood of a placebo effect
contributing to the observed hearing response was unlikely. Statistical
significance between PTA and WRS of responders and nonresponders
was calculated using 2-tailed Mann-Whitney test (Graph Pad Prism). A
P value less than 0.05 was considered significant.
Study approval. We conducted these studies as a phase I/II
open-label, single-arm, single-institution study. An IND to perform
these studies, IRB approval from the North Shore–LIJ Health System, and clinical trial registry (NCT01267994) was obtained prior
to the inception of the trial. Because A. Vambutas and the Feinstein
Institute for Medical Research have filed a patent for the use of
IL-1 antagonists in the treatment of AIED, SSNHL, and Meniere’s
disease, an external DSMB was assembled to periodically review
safety (approximately biyearly), and an internal monitoring system
to assess safety and efficacy as well as to verify source data was also
established and conducted by the Feinstein Institute for Medical
Research Office of Research Compliance. Written, informed consent was obtained from all enrolled patients from an investigator
without a conflict of interest.
Assessment of adverse events. In order to ascertain the number,
frequency, and duration of adverse events, patients were required to
maintain daily symptom logs in addition to periodic review during
interval visits. Adverse events are shown in Table 2. The daily questionnaire consisted of questions related to anticipated injection site
reactions, change in hearing, or associated symptoms of tinnitus or
vertigo. Furthermore, an open response field permitted the enrolled
patient to report any new symptoms. Logs were reviewed daily as
received, and unanticipated symptoms prompted follow-up by telephone. In several cases, the patients were requested to return to the
office for an unscheduled visit to better ascertain the severity of the
adverse event. No serious adverse events were reported or recorded.
In 2 cases, the drug was temporarily suspended because of an adverse
event. In these cases, further drug was discontinued because of significant, intolerable injection site reactions, 1 in combination with a
presumptive allergic reaction manifested by wheezing.
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